Hansa Biopharma (HNSA) Q2 2024 earnings summary

Executive summary

• Achieved third consecutive quarter of strong sales, with Q2 2024 revenue of SEK 54.2 million, including SEK 47.1 million from Idefirix sales.

• Expanded Idefirix market access, now commercial in all top five European markets and reimbursed in 14–15 countries, covering 75% of the EU transplant market.

• Completed full randomization of pivotal U.S. phase 3 ConfIdeS trial in kidney transplantation; BLA submission to FDA planned for H2 2025.

• Advanced clinical pipeline in autoimmune diseases, gene therapy collaborations, and progress in anti-GBM and PAES studies.

• Raised SEK 372 million in Q2 2024 via direct share offering, extending cash runway into 2026 and supporting U.S. launch preparations.

Financial highlights

• Q2 2024 revenue: SEK 54.2 million; product sales SEK 47.1 million before a SEK 19.9 million provision for discounts and sales adjustments.

• Operating loss for Q2 2024: SEK 187.4 million; H1 2024: SEK 346.8 million.

• SG&A expense in Q2: SEK 88–106 million; H1: SEK 179 million, including restructuring reserve.

• R&D expense in Q2: SEK 92–103 million; H1: SEK 195 million, including restructuring reserve.

• Cash and cash equivalents at June 30, 2024: SEK 705 million.

Outlook and guidance

• Expect continued Idefirix sales growth as new markets like Italy and Spain contribute.

• Gross margin anticipated to improve in H2 2024 as manufacturing costs normalize.

• Cash runway projected into 2026, supported by cost savings, top-line growth, and recent financing.

• BLA submission for imlifidase in kidney transplantation planned for H2 2025, with U.S. launch strategy focused on ConfIdeS centers and high-volume transplant centers.

• Key trial data readouts, including ConfIdeS and PAES, expected in 2025.